Literature DB >> 28775245

The necessity of external validation in exhaled breath research: a case study of sarcoidosis.

Rianne R R Fijten1, Agnieszka Smolinska, Marjolein Drent, Jan W Dallinga, Remy Mostard, Daniëlle M Pachen, Frederik J van Schooten, Agnes W Boots.   

Abstract

As in other disciplines of 'omics' research, reproducibility is a major problem in exhaled breath research. Many studies report discriminatory volatiles in the same disease, yet the similarity between lists of identified compounds is low. This can occur due to many factors including the lack of internal and, in particular, external validation. In an ideal situation, an external validation-sampled at, for example, a different location-is always included to ensure generalization of the observed findings to a general population. In this study, we hypothesized that sarcoidosis patients and healthy controls could be discriminated based on a group of volatile organic compounds (VOCs) in exhaled breath and that these discriminating VOCs could be validated in an external population. The first dataset consisted of 87 sarcoidosis patients and 27 healthy controls, whereas the validation dataset consisted of 25 patients and 29 controls. Using the first dataset, nine VOCs were found that could predict sarcoidosis with 79.4% accuracy. Different types of internal and external validation were tested to assess the validity of the nine VOCs. Of the internal validations, randomly setting aside part of the data achieved the most accurate predictions while external validation was only possible by building a new prediction model that yielded a promising yet not entirely convincing accuracy of 74% due to the indirect approach. In conclusion, the initial results of this study are very promising but, as the results of our validation set already indicated, may not be reproducible in other studies. In order to achieve a reliable diagnostic breath fingerprint for sarcoidosis, we encourage other scientists to validate the presented findings. TRIAL REGISTRATION: NCT00741572 & NCT02361281.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28775245     DOI: 10.1088/1752-7163/aa8409

Source DB:  PubMed          Journal:  J Breath Res        ISSN: 1752-7155            Impact factor:   3.262


  4 in total

1.  Breath analysis for the detection of digestive tract malignancies: systematic review.

Authors:  K F H Hintzen; J Grote; A G W E Wintjens; T Lubbers; M M M Eussen; F J van Schooten; N D Bouvy; A Peeters
Journal:  BJS Open       Date:  2021-03-05

2.  A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation.

Authors:  Wadah Ibrahim; Sushiladevi Natarajan; Michael Wilde; Rebecca Cordell; Paul S Monks; Neil Greening; Christopher E Brightling; Rachael Evans; Salman Siddiqui
Journal:  ERJ Open Res       Date:  2021-08-31

3.  Diagnostic Performance of Electronic Nose Technology in Sarcoidosis.

Authors:  Iris G van der Sar; Catharina C Moor; Judith C Oppenheimer; Megan L Luijendijk; Paul L A van Daele; Anke H Maitland-van der Zee; Paul Brinkman; Marlies S Wijsenbeek
Journal:  Chest       Date:  2021-10-28       Impact factor: 9.410

4.  External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma.

Authors:  Eline Janssens; Eline Schillebeeckx; Kathleen Zwijsen; Jo Raskin; Joris Van Cleemput; Veerle F Surmont; Kristiaan Nackaerts; Elly Marcq; Jan P van Meerbeeck; Kevin Lamote
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.